KX2-391 dihydrochloride: Dual Src and Tubulin Inhibitor for Oncology and Antiviral Research

Executive Summary: KX2-391 dihydrochloride is a small-molecule inhibitor with dual mechanisms targeting Src kinase and tubulin polymerization, validated in both in vitro and clinical settings (Moore et al., 2024). The compound demonstrates potent anti-proliferative activity with IC50 values in the nanomolar range in multiple cell types. Clinically, its 1% topical formulation is approved for actinic keratosis, showing reduction in oncogenic pathway proteins and HPV oncoprotein expression. KX2-391 dihydrochloride is also effective against hepatitis B virus (HBV) replication and botulinum neurotoxin A (BoNT/A) activity. Its pharmacological profile is well-characterized, with high selectivity and favorable tolerability in both preclinical and clinical studies (APExBIO).

Biological Rationale

KX2-391 dihydrochloride (CAS No. 1038395-65-1), also known as Tirbanibulin dihydrochloride or KX-01 dihydrochloride, acts as a dual Src kinase and tubulin polymerization inhibitor. Src kinases are non-receptor tyrosine kinases regulating cellular proliferation, invasion, and survival (Moore et al., 2024). Tubulin polymerization is essential for mitotic spindle formation and cell division. Inhibiting these pathways disrupts oncogenic signaling and cell cycle progression. Additionally, KX2-391 dihydrochloride suppresses HBV transcription and inhibits neurotoxic activity of BoNT/A by distinct molecular interactions. Its multi-target profile enables research spanning oncology, virology, and neurobiology. The compound's clinical approval for actinic keratosis underscores its translational significance.

Mechanism of Action of KX2-391 dihydrochloride

KX2-391 dihydrochloride inhibits Src kinase by binding to the substrate-binding site in a non-ATP-competitive manner. This blocks downstream targets in the Src-MEK-ERK pathway, leading to reduced cell proliferation and survival. The compound also binds a novel site on the α-β tubulin heterodimer, disrupting tubulin polymerization required for mitosis (Related analysis). In antiviral studies, KX2-391 dihydrochloride suppresses HBV transcription by targeting the HBV precore promoter. It inhibits BoNT/A activity by directly interacting with the BoNT/A light chain, preventing SNAP-25 cleavage. These mechanisms are independent and allow use in multifactorial disease models.

Evidence & Benchmarks

• Demonstrates Src kinase inhibition with IC50 values of 23 nM (NIH3T3/c-Src527F) and 39 nM (SYF/c-Src527F) cells (APExBIO).
• Inhibits tubulin polymerization at ≥80 nM, a concentration validated in vitro (Moore et al., 2024).
• Reduces HeLa (HPV-18+) cell proliferation with IC50 = 31.49 nM; downregulates Src, phospho-Src, Ras, c-Raf, ERK1/2, E6/E7, Rb, MDM2, E2F1, and invasion markers; increases cPARP (apoptosis) (Moore et al., 2024).
• Suppresses HBV replication with EC50 = 0.14 μM in PXB cells and 2.7 μM in HepG2-NTCP cells (APExBIO).
• Inhibits BoNT/A activity at 10–40 μM by blocking SNAP-25 cleavage in vitro (APExBIO).
• Clinically approved as a 1% ointment for actinic keratosis; resolves HPV(+) SCC and other lesions (Moore et al., 2024).
• Shows good clinical tolerability without significant peripheral neuropathy (Moore et al., 2024).

Applications, Limits & Misconceptions

KX2-391 dihydrochloride is widely utilized in cancer research to dissect Src kinase signaling, tubulin polymerization, and cell cycle regulation (Mechanistic Insights). It is effective in studies of HPV-associated cancers, HBV replication, and BoNT/A neurotoxicity. The compound’s dual targeting allows researchers to interrogate crosstalk between kinase and cytoskeleton pathways. In vitro, it is used at 0.013–10 μM for cancer and HBV models, and 10–40 μM for neurotoxin assays. In vivo, oral dosing in mice is 5–15 mg/kg, and in chimpanzees (anti-HBV), 1 mg/kg twice daily. Clinically, topical 1% ointment is standard for actinic keratosis, and oral dosing ranges from 40–120 mg/day for tumor treatment, reaching plasma Cmax of 61–218 ng/mL. Effective anti-HBV plasma concentrations are ≥560 nM (241.92 ng/mL), with high selectivity indices (450 in PXB, >37 in HepG2-NTCP).

Common Pitfalls or Misconceptions

• KX2-391 dihydrochloride is not a general cytotoxic agent; its activity is pathway-specific and concentration-dependent.
• The compound is insoluble in water; use DMSO or ethanol (with gentle warming) for stock solutions.
• It is not effective for all viruses; validated antiviral activity is specific to HBV.
• Peripheral neuropathy is not a major toxicity, but long-term systemic effects require further study.
• KX2-391 dihydrochloride’s efficacy in non-keratinocyte skin cancers or non-HPV+ lesions is not fully established.

This article extends prior analyses by providing up-to-date, quantitative clinical and mechanistic data on KX2-391 dihydrochloride, contrasting with the broader overviews at KX2-391 Dihydrochloride: Mechanistic Insights and Beyond Src Inhibition in Oncology by detailing specific evidence, clinical benchmarks, and workflow recommendations. For cell assay optimization, see guidance in Optimizing Cell-Based Assays with KX2-391 dihydrochloride, which this article updates by integrating new clinical tolerability and selectivity data.

Workflow Integration & Parameters

Preparation: Dissolve solid KX2-391 dihydrochloride (MW 504.45) in DMSO (≥25.2 mg/mL) or ethanol (≥48.8 mg/mL, gentle warming). Store at -20°C. Use fresh solutions for short-term experiments. For in vitro studies, typical working concentrations are 0.013–10 μM (Src/tubulin/HBV) and 10–40 μM (BoNT/A). Validate activity in appropriate cell models (e.g., NIH3T3/c-Src527F, HeLa, PXB, HepG2-NTCP). In vivo, oral dosing in mice is 5–15 mg/kg, once or twice daily. For topical clinical use, apply 1% ointment once daily for 5 days. Always monitor for cell-type specific cytotoxicity and off-target effects. Source KX2-391 dihydrochloride (SKU A3535) from APExBIO (official product page).

Conclusion & Outlook

KX2-391 dihydrochloride is a validated, dual mechanism inhibitor for probing Src kinase and tubulin polymerization pathways. It is an established tool in cancer, antiviral, and neurotoxin research, with demonstrated efficacy and safety in both preclinical and clinical contexts. Its dual action and favorable profile support further translational research and potential expansion into new clinical indications. For verified supply and documentation, APExBIO remains the primary source.